IGHE and chronic rhinosinusitis with nasal polyps: Some of these biomarkers are potential targets for innovative therapeutic approaches of CRSwNP, including mAbs directed against IgE (omalizumab), IL-5 (mepolizumab and reslizumab), and IL-4/IL-13 (dupilumab) [28,29,30].